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Abstract 
Methamphetamine (MA) use during pregnancy is associated with a range of adverse 
neurodevelopmental implications for a developing fetus.  This systematic review examines 
studies which report the effects of prenatal MA exposure in utero on infant and child 
behavioural development.  A systematic search of PSYCINFO, Scopus, PubMed and ERIC 
databases was conducted and 839 records were identified.  A total of 15 articles met inclusion 
criteria, examining behavioural outcomes in children from birth to nine years of age.  This 
review found consistent reports of behavioural dysregulation in neonates and children 
prenatally exposed to MA.  Furthermore, the results indicate that children with prenatal MA 
exposure display more pronounced behavioural difficulties as they age.  However, the small 
number of longitudinal studies and the narrow breadth of populations sampled limits the 
interpretation and generalisability of these findings.  Future research should consider these 
limitations and conduct longitudinal studies, with a broader range of population samples, to 
determine the temporal association between prenatal MA exposure and behavioural 
outcomes.  These findings have implications for early identification and prevention of later 
behavioural dysfunction as a result of prenatal MA exposure.  It is crucial to prevent maternal 
MA use during pregnancy and to provide postnatal service care for parents of children with 
prenatal MA exposure; so they have to ability to support and promote a more adaptive 
developmental trajectory for their child.  
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The Impact of Maternal Prenatal Methamphetamine Exposure on Child Behavioural 
Development: A systematic review 
The growing use of amphetamine-type substances (ATS) is a world-wide concern.  
The United Nations Office on Drugs and Crime (UNODC) reported that in 2016, an 
estimated 34.2 million people world-wide had used an ATS in the past year (UNODC, 2018).  
One specific type of amphetamine, methamphetamine (MA), is of growing concern to health 
professionals (UNODC, 2018).  In the U.S. alone, 1.39 million people reported MA use in the 
year of 2016 (Substance Abuse and Mental Health Service Administration, 2017).  
Furthermore, women account for a substantial amount of MA users, with data showing that 
44% of the 1.39 million people were women (SAMHSA, 2017).  The use of MA has 
noticeable effects on the behaviour of its users; including, aggression, behavioural 
disinhibition, poor impulse control, inattention, anxiety, depression and irritability (Brown & 
Hohman, 2006; Cruickshank & Dyer, 2009; Murray, 1998). 
This review is focused on the use of MA by women during pregnancy. There is little 
information detailing the outcomes for children exposed to MA in utero. The most recent 
Treatment Episode Data Set (TEDS) from the U.S reported that in 2016, 20% of pregnant 
women admitted to federally funded substance abuse centres were there for MA exposure 
(SAMHSA, 2016).  The current review examines studies reporting on the impact of prenatal 
methamphetamine exposure (PME) on a child’s behavioural development. 
 
Neurotoxicity of Methamphetamine  
Methamphetamine is a central nervous system (CNS) stimulant that predominantly 
acts on the sympathetic nervous system (Courtney & Ray, 2014).  It causes a release of 
dopamine, serotonin and norepinephrine, and inhibits the reuptake of these transmitters.  
Initially, increased dopamine in the brain’s reward centre results in intense euphoria, arousal 
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and behavioural disinhibition (Cruickshank & Dyer, 2009).  However, prolonged MA abuse 
can result in impairments in motor control, memory, learning and behavioural function (Barr 
et al., 2006; Meredith, Jaffe, Ang-Lee, & Saxon, 2005; Volkow et al., 2001).  It is postulated 
the these impairments are associated with the neurotoxic effects of MA (Barr et al., 2006; 
Meredith et al., 2005).  The term ‘neurotoxicity’ indicates any adverse changes in the 
structure and/or function of the nervous system as a result of a biological, physical or 
chemical agent. (Cho & Melega, 2002; Erinoff, 1995).  Animal models have demonstrated 
the neurotoxicity of methamphetamine; showing distinct anatomic deterioration of 
dopaminergic pathways in the striatum of MA-exposed mice (Barr et al., 2006; Miller & 
O’Callaghan, 2003) and a long-term decrease in dopamine transporter (DAT) density in non-
human primates (Villemagne et al., 1998).   
Although the mechanisms of action of MA are not completely understood, researchers 
investigating the neurotoxic effects of MA in human studies suggest that prolonged MA 
abuse has similar adverse effects on the dopaminergic systems as in the animal models (Cho 
& Melega, 2002; Ernst, Chang, Leonido–Yee & Speck, 2000; Wilson et al., 1996). Volkow et 
al. (2001) used positron emission tomography (PET) to demonstrate a reduction in striatal 
DAT density is associated with long-term MA abuse in adult users.  Several studies have also 
shown MA-induced structural and metabolic alterations to a number of brain areas, including 
the hippocampus (Thompson et al., 2004), thalamus (Volkow et al., 2001) and basal ganglia 
(Chang et al., 2005) in both current and abstinent MA users.  Furthermore, researchers have 
demonstrated an association between MA-induced neurostructural damage and altered 
cognitive and affective function in adult users (Tanabe et al., 2009; Thompson et al, 2004; 
Volkow et al., 2001).  
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Modes of Prenatal Methamphetamine Exposure  
Given the neurotoxic effects of long-term MA exposure in adults, researchers have 
proposed that prenatal MA exposure may also induce similar effects on fetal 
neurodevelopment (Frost, 2000; Salisbury, Ponder, Padbury, & Lester, 2009; Warton et al., 
2018).  The term ‘neurodevelopment’ refers to the brain’s development of neurological 
pathways which impact on an individual’s performance and functioning (Neurodevelopment, 
n.d.).  It has been established that MA readily crosses the placenta and blood-brain barrier 
(Garcia-Bournissen, Rokach, Karaskov, & Koren, 2007; Joya, Pacifici, Salat-Batlle, Garciá-
Algar, & Pichini, 2015).  Furthermore, preclinical models have demonstrated the 
vasoconstrictive effects of MA exposure in utero (Burchfield, Lucas, Abrams, Miller, & 
DeVane, 1991; Stek et al., 1993), resulting in decreased placental blood flow and fetal 
hypoxia (Stek, Baker, Fisher, Lang, & Clark, 1995), which can have adverse effects on a 
developing fetus (Thompson, Crimmins, Telugu, & Turan, 2015).  
Fetal exposure to MA can occur in a number of different ways.  First, a fetus can be 
directly exposed to MA in utero via maternal use (i.e. direct exposure).  Second, an infant can 
be exposed by inhaling fumes from MA use while family members are using the drug within 
the child’s environment in the postnatal period (i.e. passive exposure via second-hand smoke 
inhalation).  Also an infant could be passively exposed through MA-contaminated clothing or 
surfaces in the home (Brown & Hohman, 2006).  Third, children born to women who use MA 
are likely to also be exposed to a suboptimal home environment and reduced parental care 
(Derauf, LaGasse, et al., 2012; Nguyen et al., 2010).  Therefore, these would be considered 
indirect effects of MA-exposure, for example, neglect or domestic violence in the home 
(Dowling & Morgan, 2018).  While it is imperative to understand the evidence detailing how 
different modes of exposure might impact on fetal and child development, given the scope of 
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the current paper, only studies assessing the effects of direct MA exposure will be included in 
the review.   
Neurodevelopmental Effects of Prenatal Methamphetamine Exposure Via Maternal Use 
The literature in this area of research uses the term ‘neurodevelopment’ as an 
overarching concept which encompasses a number of different domains relating to growth 
and development.  These include; cognitive (e.g. memory, attention and IQ), language (e.g. 
receptive and expressive language) behavioural and emotional (e.g. emotional regulation, 
internalising and externalising behaviours), psychomotor (e.g. gross and fine motor skills) 
and neuroanatomical (e.g. development of CNS and brain structures) domains. 
It is reasonable to postulate that exposure to methamphetamine in utero, during a 
neurologically vulnerable period, might produce serious neurostructural alterations, which 
might subsequently lead to neurodevelopmental impairments in a developing fetus (Salisbury 
et al., 2009; Sowell et al., 2010).  Previous research investigating the neurodevelopmental 
implications of PME have found changes in infant brain structures when they are prenatally 
exposed to MA.  A recent study by Warton et al. (2018) investigated the potential changes of 
white-matter integrity in the striatal-orbitofrontal circuit in neonates prenatally exposed to 
MA.  They utilised a case-control design with 23 infants (11 exposed) and found that 
increased MA use was associated with reduced white-matter connections in the striatum, 
midbrain and orbitofrontal cortex.  There were some limitations to this particular study, 
including a small sample size and inconsistent p values used for the statistical analyses.  
Nonetheless, this paper is one of several neurological studies which report neurostructural 
changes in an infant’s brain following MA exposure.  Other studies have found reduced 
caudate volume (Sowell et al., 2010; Warton et al., 2018); and smaller subcortical volumes, 
which were associated with attention and verbal memory deficits (Chang et al., 2004).   
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In addition, researchers have observed a number of neuropsychological and 
behavioural differences between infants exposed to MA in utero and healthy controls, 
including; reduced fine motor control (Smith et al., 2011); deficits in inhibitory control 
(Derauf, LaGasse, et al., 2012); and increased emotional reactivity and externalising 
behaviours (LaGasse et al., 2012).  Considering the widespread use of MA in pregnancy 
(SAMHSA, 2016), the influence of PME on fetal development and child neurodevelopmental 
outcomes is of particular clinical importance.  
The Present Review 
In order to provide health professionals, policy makers and parents with an accurate 
and informative education on the effects of PME on fetal and child development, it is 
imperative to systematically examine and understand this area of research.  However, given 
the volume of studies produced by researchers in this field, the current review will be limited 
to behavioural outcomes. 
Behavioural dysfunction has the potential to permeate and negatively influence many 
aspects of daily life; for example, high levels of externalising behaviours have been 
associated with poor school performance and educational attainment (Breslau, Lane, 
Sampson, & Kessler, 2008).  Furthermore, it is essential to examine behavioural outcomes 
specifically, given that behavioural difficulties are more perceptible in the early years of a 
child’s life, prior to school entrance (van Dyk, Ramanjam, Church, Koren, & Donald, 2014), 
and may therefore be used as an early marker to identify children who may later experience 
other deficits as a result of MA exposure (Abar et al., 2013).  As such, early detection of 
behavioural dysfunction allows for early intervention to support more adaptive functioning. 
At this time, to our knowledge, there are no systematic reviews investigating how 
pregnancy-related MA exposure impacts on infant and child behavioural outcomes only.  
Therefore, the purpose of the following review was to examine and synthesise the available 
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literature to provide this area of research with a comprehensive understanding of how PME 
effects infants and child behavioural development.  The results of the review indicate where 
additional research is required and provide considerations to improve future studies. 
 
Method 
Preliminary Search Strategy  
The primary objective of the current search strategy was to identify all published peer-
reviewed studies reporting the prevalence of behavioural outcomes in a population of infants 
and/or children prenatally exposed to methamphetamine, through maternal use.  A systematic 
search strategy was developed by two independent researchers. The search of abstracts and 
titles of peer-reviewed articles was conducted using PSYCINFO, PubMed, Scopus and ERIC 
databases including papers up to September 2019. Search results were not limited to a specific 
date range. In order to identify studies investigating prenatal exposure to methamphetamine 
and behavioural outcomes the following terms were used to systematically search databases: 
“prenatal OR maternal,” AND “methamphetamine OR meth,” AND “exposure,” AND 
“neurodevelopment* OR ‘child development’ OR neurobehavioural”. 1    Furthermore, the 
reference lists of all relevant studies were searched to identify any additionally relevant studies 
not found in the search. 
 
Inclusion and Exclusion Criteria 
For inclusion in the review, studies had to: 1) involve human subjects only, 2) be peer 
reviewed, 3) conduct formal assessment of at least one behavioural outcome using a validated 
test, 4) assess the behavioural outcomes of children and/or infants exposed to 
 
1 While the current review only focused on behavioural outcomes, previous studies (Dixon, Kurtz, & Chin, 
2008) have used the terms ‘neurodevelopmental’ and ‘neurobehavioural’ interchangably, encompassing 
‘behavioura’ outcomes as well.  Therefore, broad search terms (i.e. ‘neurodevelopment*’ and 
‘neurobehavioural’) were used to ensure that all relevant studies could be identified in the database search.   
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methamphetamine in the prenatal period through maternal use, and 5) adhere to an 
observational study methodology.  Observational study designs included were cohort studies, 
case-control studies and cross-sectional studies, whereas intervention studies were excluded.  
Papers published in a language other than English were translated by a native speaker and 
reviewed.  Studies that included a cohort of individuals prenatally exposed to 
methamphetamine via maternal use, that were part of a single larger study, were included if the 
analysis of this particular sub-cohort was reported separately.  Studies were excluded if: 1) they 
involved non-human subjects, 2) they were grey literature, 3) outcome measures assessed 
neurodevelopmental outcomes only, and 4) study design was experimental. 
 
Implementation of Search Strategy and Data Extraction 
  One independent reviewer ran the search using the key terms described above.  Using 
the inclusion and exclusion criteria, each study was screened for relevance based on the title 
and abstract.  If the researcher could not ascertain the studies’ relevance from the title and 
abstract, the full text was assessed independently.  The eligibility of the resulting studies was 
then assessed by reading the full text articles based on the inclusion and exclusion criteria.  At 
this point, if the researcher could not establish an article’s eligibility, a second independent 
reviewer was consulted.  Discrepancies were resolved through review and discussion with all 
authors until consensus was achieved.  All excluded articles and reasons detailing their 
exclusion were documented (see Figure 1).  A hand search of the reference lists from relevant 
papers produced no further relevant papers. 
For the eligible studies, data were collected regarding characteristics including author, 
study year, study design, groups compared, method identifying methamphetamine exposure, 
study sample size, infant age at testing, sex of the infant, outcome measure(s) assessing 
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neurobehavioural outcomes, covariates and statistical analysis.  For group comparisons, 
Cohen’s d was calculated using M and SD where reported. 
 
Risk of Bias and Quality Assessment 
 A quality assessment of all eligible studies meeting full inclusion and exclusion 
criteria was conducted using the Newcastle-Ottawa Quality Assessment Scale (NOQAS) 
(Wells et al., 2009).  Each study was given a star rating in three categories by one reviewer 
(selection, comparability and exposure/outcome) using either the case control assessment 
scale, the cohort studies assessment scale or the cross-sectional studies assessment scale, 
depending on the study’s methodology.  The first category assessed the selection of study 
groups (cases or cohorts); the second category assessed the comparability of cases and 
controls (or cohorts); and the third category assessed exposure (for case control studies) or 
outcome (for cohort studies).  The quality of the studies was rated (good, fair and poor) by 




The search outlined above yielded a total of a total of 839 articles from four 
databases.  After 55 duplicates were removed, the remaining 784 articles were screened for 
relevance firstly by title and abstract.  Following extensive title and abstract screening, 762 
articles were excluded, which left 22 articles to be assessed for full-text eligibility.  Of the 
papers assessed for full-text eligibility, a total of seven articles were excluded; four articles 
reported other outcomes of interest, two articles had other study methodologies, and one 
article was of poor quality as assessed by the NOS.  Finally, 15 papers met all of the 
inclusion and exclusion criteria (see Figure 1). 























Figure 1. Identification of studies for inclusion in systematic review.  
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Study Characteristics  
 The characteristics of each study are summarised in Table 1.  Studies took place in the 
USA, South Africa and New Zealand.  13 of the 15 articles were a part of a single larger 
study, called the Infant Development, Environment, and Lifestyle (IDEAL) Study, while the 
remaining two articles were conducted independent of the IDEAL Study.  This does 
introduce important limitations to the breath of populations sampled and will be discussed 
further below. To identify MA exposure, the IDEAL studies used the Substance Use 
Inventory (self-report maternal exposure to MA) and positive meconium screening confirmed 
by positive gas chromatography-mass spectrometry, the van Dyk et al. (2014) paper used 
self-report only and the Piper et al. (2011) paper used medical records only.  The sample 
sizes ranged from 35 to 559 total participants and child assessments ranged in age from birth 
to nine years.  13 studies reported roughly equal participants sex ratios, with the exception of 
van Dyk et al., (2014) reporting 36% female and Galland, Mitchell, Thompson and Wouldes 
(2013) not reporting participant sex ratio.  Outcome measures included the NICU Neonatal 
Neurobehavioural Scale (NNNS), the Child Behaviour Checklist (CBCL), the Connors 
Kiddie Continuous Performance Test (K-CPT), Connors Behaviour Rating Scale (CBRS-R), 
The Behaviour Rating Inventory of Executive Function (BRIEF), and endocrine measures of 
stress reactivity in the form of cortisol reactivity and arousal thresholds.  In general, the 
quality scores were of fair to good quality; with ratings ranging between 5 and 9 out of a 
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Table 1. 
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Neurobehavioural Outcomes 
Neonate neurobehavioural dysfunction.  
The NICU Neonatal Neurobehavioural Scale. In a sample of 166 mothers recruited 
from the U.S. and in another sample of 559 mothers recruited from the U.S. (N = 379) and 
New Zealand (N = 180), Smith et al. (2008) and LaGasse et al. (2011) assessed neonatal 
outcomes between birth and 5 days.  Smith et al. (2008) found PME to be associated with 
greater physiological stress in neonates (Cohen’s d = .21).  LaGasse et al. (2011) reported 
that neonates with PME exhibited poorer quality of movement (Cohen’s d = .31), greater 
total stress abstinence (Cohen’s d = .18), greater physiological stress (Cohen’s d = .23) and 
greater CNS stress (Cohen’s d = .12).  In a sample of 380 mothers recruited from the U.S., 
Kiblawi et al. (2014) assessed neurobehavioural outcomes in neonates between birth and one 
month.  They did not report any significant differences between MA-exposed and comparison 
neonates solely based on exposure status (Cohen’s d’s ≤ .32).  However, for MA-exposed 
neonates, they reported a significant increase in arousal levels (Cohen’s d = .27) and an 
overall decrease is stress levels (Cohen’s d = .40) in MA-exposed neonates between birth and 
one month.  Therefore, infants with PME were less drowsy and stressed by one month of age. 
 
Infant and child neurobehavioural dysfunction.  
Endocrine measures of stress reactivity.  Galland et al. (2013) used EEG recordings 
to assess sleep arousal thresholds in a sample of 99 three-month-old infants.  They reported 
no significant differences in arousal thresholds between MA-exposed infants and the 
comparison groups.  These results indicated that PME was not associated with adverse 
neurobehavioural outcomes in relation to sleep-wakefulness patterns in infants aged three 
months old.  However, as effect sizes could not be calculated these results were interpreted 
with caution.  Kirlic and colleagues (2013) assessed cortisol reactivity using saliva samples in 
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123 MA-exposed children aged two years.  They found that PME predicted increased cortisol 
reactivity, therefore higher stress levels, after a stress inducing situation (Cohen’s d = .30).  
However, as this study does not have a comparison group, these findings do not delineate 
differences in cortisol reactivity between children with PME and healthy controls.  Therefore, 
the interpretation of these findings was limited. 
The Child Behaviour Checklist.  Seven articles used the CBCL as their primary 
outcome measure of behaviour to detect emotional and/or behavioural problems in their 
samples. Five of the seven articles reported an effect of PME on child behavioural outcomes.  
van Dyk et al. (2014) assessed 36 South African children aged between two and four years.  
They reported that MA-exposed children exhibited elevated t-scores on the internalising 
behaviour (Cohen’s d = .19) and externalising behaviour (Cohen’s d = .53) problem scales.  
Although, these scores were not significantly different in comparison to the control group.  
The small effect size and insignificant p value suggests that there was no real effect of PME 
on internalising behaviours; however, for externalising behaviours, the medium effect size 
suggests that there was a difference between groups with and without PME.  The study may 
not have been sufficiently powered to detect this effect given the small sample size.    
In the U.S. sample of children with PME, Derauf and colleagues (2012) assessed a 
sample of 35 children at three years and reported no statistically significant differences in 
CBCL internalising (Cohen’s d = .34), externalising (Cohen’s d = .12) or total problem 
(Cohen’s d = .10)  scores between groups.  Once again, given the small sample size of this 
study, it is possible that a difference could not be detected due to a lack of power.  Twomey 
et al. (2013) assessed 214 children aged 5 years and found significant associations between 
PME and externalising behaviours (Cohen’s d = .48), reporting MA-exposed children were 
more than twice as likely to exceed the clinical cut-off for externalising behaviour problems 
than comparison children.  There were no statistically significant differences between 
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internalising (Cohen’s d = .11) and total behaviour problem scores (Cohen’s d = .06) between 
the exposed and non-exposed groups.  LaGasse and colleagues (2012) assessed a sample of 
330 children between three and five years old.  They found that PME was associated with 
increased anxious/depressed problems (age 3: Cohen’s d =.18; age 5: Cohen’s d =.15) and 
increased emotional reactivity (age 3: Cohen’s d =.18; age 5: Cohen’s d =.14) across ages 
three and five.  In addition, PME was associated with greater externalising problems 
(Cohen’s d = .13) and ADHD problems (Cohen’s d = .12) at age 5 but not age three (Cohen’s 
d’s ≤ .04).  They found no other significant differences between groups of children with and 
without PME across ages (Cohen’s d’s ≤ .14). 
In a sample of 320 children, Abar et al. (2013) reported increased emotional reactivity 
(Cohen’s d = .26), anxious/depressed problems (Cohen’s d = .27) and aggression (Cohen’s d 
= .27) in children with PME at 5 years of age.  On the withdrawn, sleep problems and 
somatic complaints subscales, they did not report significant differences based on MA 
exposure (Cohen’s d’s ≤ .12).  However, the effects of PME on behavioural and emotional 
control problems and later executive function deficits were mediated by early adversity; 
therefore, PME was indirectly associated with these outcomes.  In a sample of 290 children 
aged 7.5 years, Eze and colleagues (2016) found PME to be significantly associated with 
increased externalising (Cohen’s d = .26), rule-breaking (Cohen’s d = .30) and aggressive 
behaviour (Cohen’s d = .30).  They did not report significant differences between children on 
internalising (Cohen’s d = .16) and total problems (Cohen’s d = .15) scales.  Mediation 
analysis highlighted that the relation between PME and behavioural problems was 
significantly mediated by early adversity, therefore, demonstrating that early adversity was a 
greater predictor of behavioural problems in children at 7.5 years.   
Himes and colleagues (2014) assessed the impacts of PME on children aged 6.5 and 
7.5 years.  They found that PME predicted child neurobehavioural disinhibition as measured 
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by their total scores on the Child Memory Scale, CBCL and CPRS-R combined.  They also 
assessed whether postnatal MA-exposure would significantly predict behavioural problems in 
children.  They found that postnatal MA-exposure alone did not significantly predict 
neurobehavioural disinhibition, therefore highlighting the particular contribution of PME on 
later behavioural difficulties.  Individual scores relating to their measure of neurobehavioural 
disinhibition were not reported, which meant that effects sizes could not be calculated. 
Therefore, the interpretation of these results in relation to behavioural dysfunction, as defined 
by the current review, was limited. 
Connors Kiddie Continuous Performance Test. Derauf and colleagues (2012) also 
reported that children with PME had poorer scores on the K-CPT, indicating that they had 
greater difficulty with sustained attention (Cohen’s d = .70) and adjusting to changing task 
demands (Cohen’s d = 1.21).  In a sample of 301 children aged 5.5 years, Kiblawi et al. 
(2013) found children with PME had an increased risk of developing ADHD than children 
without PME (Cohen’s d = .60).  They also found that children with PME were more likely to 
exhibit difficulties with sustained attention and less consistent reaction times; however, effect 
sizes could not be calculated based on the data reported in the paper, thus, results were 
interpreted with caution.  Piper and colleagues (2011) assessed a sample of 66 children 
between seven and nine years.  They found no significant difference between groups based 
on MA exposure, therefore, indicating that that PME had no effect on vigilance, impulsivity 
or inattentiveness as measured by the K-CPT.   
Behaviour Rating Inventory of Executive Function.  Furthermore, when comparing 
parental ratings of executive function between children with and without PME, there was a 
significant difference between ratings on the behavioural regulation scale (Piper et al., 2011).  
Results indicated that children with PME have difficulty with impulse control, therefore the 
ability to stop their behaviour at an appropriate time.  There were no differences between 
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groups in their ability to regulate their emotional responses and shift between activities and 
places without difficulty.  However, Cohen’s d effect sizes were unable to be calculated 
based on the data reported in the Piper et al. (2011) paper, and so the results were interpreted 
with caution. 
Connors Parent Report Scale.  In a sample of 298 children, Diaz and colleagues 
(2014) found that prenatal methamphetamine exposure was not associated with oppositional 
behaviours (Cohen’s d = .19), hyperactivity (Cohen’s d = .26) and ADHD problems (Cohen’s 
d = .22) in children aged 7.5 years. 
 
Discussion 
The data suggest that PME has an impact on infant and child behavioural outcomes.  
More specifically, the results indicate that children with PME display more pronounced 
behavioural difficulties as they age, in comparison to children without PME.  To place the 
current findings in context, it is valuable to compare the results to reviews investigating the 
effects of prenatal cocaine exposure on neurobehaviour in infants and children, which is 
thought to have a similar neurochemical action on brain development (Salisbury et al., 2009).  
In neonates, neurobehavioural dysfunction five days after birth, in the form of under 
arousal, poor quality of movement and increased stress levels, was consistent with findings 
from cocaine-exposed neonates (Lester et al., 2002).  However, in cocaine-exposed neonates, 
these neurobehavioural deficits persisted up to one month after birth, variable with our 
results.  Findings from this review were also consistent with a review of 42 studies on 
prenatal cocaine exposure by Lester and LaGasse (2010) whereby adverse effects of PME 
were not observable until age five.  These findings may be attributed to a latent or “sleeper” 
teratogenic effect (Mayes & Ward, 2003) given that the effects of PME were subtler in earlier 
years of infancy and became more pronounced later in the child’s development (Lewis, 
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Galbally, Gannon, & Symeonides, 2014).  Difficulties with internalising behaviours were 
inconsistently reported and with small effect sizes.  As such, we cannot confidently propose 
that PME has an impact on internalising behaviours (e.g. anxiety, depression, social 
withdrawal).   
It is possible that PME adversely impacted on behavioural outcomes in children under 
five years of age, however, this conclusion could not be drawn based on the current evidence.  
Both Derauf et al. (2012) and van Dyk et al. (2014) had small sample sizes (N’s ≤ 35) and 
possibly lacked power to detect differences between groups with and without PME.  Overall, 
the majority of the effect sizes were within the small to medium range of Cohen’s d cut off 
scores.  While most of the effects were small, it is important to consider the clinical 
significance of these effects in the context of a child’s life.  For example, externalising 
behavioural problems are indicative of deficits in executive function, self-regulation and 
social relationships (Twomey et al., 2013), which can have serious implications for children 
and their families as they are exposed to school settings, where social, behavioural and 
academic demands increase (Shonkoff & Phillips, 2000).   
The concept of fetal programming may provide an explanation for the effects of PME 
on child behavioural outcomes.  Fetal programming refers to way in which a specific 
environmental factor modifies fetal developmental trajectories, resulting in persistent changes 
in the structure and function of biological systems.  These changes create enduring effects 
which may elicit certain responses to environmental stimuli later in development (Gluckman 
& Hanson, 2006; Lewis et al., 2014).  Preliminary evidence suggests that PME is associated 
with increased stress reactivity (Kirlic et al., 2013), which supports the hypothesis by 
Salisbury and colleagues (2009) that MA exposure relates to changes in hypothalamic-
pituitary-adrenal (HPA) system programming.  The HPA-axis is imperative not only for 
stress regulation, but also for emotions and emotion-regulation (Lupien, McEwen, Gunnar, & 
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Heim, 2009).  Lewis and colleagues highlight that dysregulation in the stress response is a 
common feature of emotional and behavioural difficulties in childhood.  As such, it is 
reasonable to suggest that MA exposure in utero may impact on HPA-axis programming, 
resulting in behavioural dysregulation in neonates and children.  It is also important to note 
that early adversity and the postnatal environment impact of the expression of behavioural 
difficulties (Lester et al., 2009).  A model proposed by Lester et al. (2009) outlines the 
cumulative effects of the prenatal and postnatal environment, and the subsequent implications 
for behavioural dysregulation in children prenatally exposed to MA. 
 
Limitations and Directions for Future Research  
It is important to highlight some of the limitations of the articles examined in the 
current review.  First, 13 of the 15 articles were a part of the IDEAL study.  Therefore, these 
inferences may not be generalisable to the wider population of women who use MA during 
pregnancy, given that the majority of findings were derived from the same, select cohort.  
Second, the main outcome measures used to quantify methamphetamine use across 
pregnancy and assess behavioural outcomes in infants and children (e.g. the CBCL, the 
BRIEF and the CPRS) were based on self-report and are less reliable than structured 
interviews by trained professionals, which may introduce reporting bias (Althubaiti, 2016).  
Third, 11 of the 15 studies were of a case-control design.  This design limits the ability to 
determine the temporal association between PME and behavioural outcomes, and the causal 
relationship between the two (Song & Chung, 2010).  Therefore, future research would 
benefit from conducting more longitudinal studies to understand the behavioural trajectories 
of children with PME (Shonkoff & Phillips, 2000), and allow for more accurate assessment 
of causality between PME and behavioural outcomes. 
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Furthermore, limitations of this review must be noted, and the findings considered in 
the light of these limitations.  This review was restricted by the bias introduced by having a 
single reviewer conduct the search protocol and data extraction.  Another restriction was the 
scope of the study; it is possible that the narrow scope may have excluded potentially relevant 
papers to contribute a broader understanding of this area of research.  Furthermore, this 
review did not delineate findings based on the timing of MA use across gestation and dose-
related effects.  This is an important outcome to understand and should be investigated in 
future research.  Given these limitations, which were predominately based on the scope of the 
review, it is recommended that a meta-analysis is conducted to examine the 
neurodevelopmental implications of PME on fetal development as a whole.  This would 
provide this area of research with a more in-depth interpretation of the overall effects of PME 
on fetal and child development.   
 
Implications for Health Professionals, Policy Makers and Parents 
In conclusion, this review has found consistent reports of behavioural dysregulation in 
children prenatally exposed to MA in utero, in the form of externalising behaviours and 
ADHD type difficulties.  These highlight the need for increased efforts to prevent maternal 
use of MA during pregnancy as well as the importance of early identification and prevention 
of behavioural dysregulation in children with PME.  In light of these results, it may be 
possible to detect children at risk of later developing dysfunctional behavioural patterns as 
early as in the neonatal period (Lester et al., 2009).  Further, if early markers are not 
identified in neonates, more perceptible behavioural problems (i.e. externalising and ADHD 
behaviours) may alert caregivers to the fact that their child is experiencing difficulties.  It is 
crucial to implement policies and practices which provide postnatal service provision for 
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caregivers of children with PME, so they have to ability to support and promote a more 
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